Latest News and Press Releases

TOKYO and CAMBRIDGE, Mass., June 09, 2024 (GLOBE NEWSWIRE) -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge,...

Upcoming community events will inform plans to create more equitable flying experiences for passengers with reduced mobility CAMBRIDGE, Mass. and ATLANTA, June 03, 2024 (GLOBE NEWSWIRE) -- Biogen...

SOD1-ALS is a devastating, uniformly fatal, and ultra-rare genetic form of ALS estimated to affect less than 1,000 people in Europe1QALSODY is Biogen’s third rare disease therapy to be approved in the...

Transaction to include felzartamab, a potential first-in-class therapeutic candidate with promise as a pipeline-in-a-product across a range of immune-mediated diseasesFelzartamab is an investigational...

Development of BIIB105, an investigational antisense oligonucleotide for amyotrophic lateral sclerosis (ALS), will be discontinued based on data from the Phase 1/2 ALSpire studyBiogen and Ionis...

TOKYO and CAMBRIDGE, Mass., May 14, 2024 (GLOBE NEWSWIRE) -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge,...

Efforts focused on four areas: access and health equity, workforce and DE&I, community impact and the environment CAMBRIDGE, Mass., May 02, 2024 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB)...

CHMP positive opinion is based on a robust analytical, non-clinical and clinical data package comparing TOFIDENCE™ to the reference product ROACTEMRA® CAMBRIDGE, Mass., April 25, 2024 (GLOBE...

New data from the RESPOND study show that neurofilament levels, an indicator of neurodegeneration, were reduced in nearly all study participants treated with SPINRAZAReductions in biomarker complement...

New data advances understanding of new approaches to treating Alzheimer’s diseaseResearch on disease progression could help inform future clinical trials CAMBRIDGE, Mass., March 04, 2024 (GLOBE...